ME 23ANDME HLDG CO

23andMe to Present at the Wells Fargo Healthcare Conference

23andMe to Present at the Wells Fargo Healthcare Conference

SUNNYVALE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that management will be participating in the Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021 at 8:20 a.m. Pacific Time / 11:20 a.m. Eastern Time.

Interested parties can access a live webcast of the presentation on the investors section of the company website at under the “News & Events” menu. The latest information on this and other events, including any changes to presentation dates and times, can also be found there. A webcast replay will be available at the same location for a limited time within 24 hours after the event.

About 23andMe

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its nearly 12 million customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at .

Forward-Looking Statements

This press release contains certain “forward-looking statements” including the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its crowdsourced research platform. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained herein are based on 23andMe’s current expectations and beliefs concerning future developments and their potential effects, but there can be no assurance that these will be as anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Investor Relations Contact:

Media Contact:

 



EN
01/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

23andMe Reports FY2023 First Quarter Financial Results

23andMe Reports FY2023 First Quarter Financial Results First quarter revenue grew 9% to $64.5 millionConsumer revenue grew 17% year over year due to the addition of telehealth revenueOn track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the first quarter (“Q1”) of its fiscal year 2023 (“FY2023”), which ended June 30,...

 PRESS RELEASE

23andMe to Report FY2023 First Quarter Financial Results

23andMe to Report FY2023 First Quarter Financial Results SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday, August 8, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on the day of the event at . A webcast ...

 PRESS RELEASE

23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results

23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results Achieved FY2022 financial guidanceFourth quarter and full year revenues of $101 million and $272 million representing 14% and 11% increases over prior year, respectivelyNew genomic health services expected in FY2023Webcast today, May 26, 2022, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today report...

 PRESS RELEASE

23andMe to Report FY2022 Fourth Quarter and Full Year Financial Result...

23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results SUNNYVALE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) fourth quarter and full year after the market closes on Thursday, May 26, 2022. The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarter’s financial results and report on business progress. The webcast can be accessed on the day of the event at . A we...

 PRESS RELEASE

23andMe to Present at American Association for Cancer Research (AACR) ...

23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company with a mission to help people access, understand, and benefit from the human genome, today announced that it will present data related to its wholly owned 23ME-00610 immuno-oncology program at the upcoming being held April 8-13, 2022 in New Orleans, Louisiana. Details for the abstract are as follows: Abstract title: Presenting author: Jill FenauxA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch